CRSP Short Interest
CRISPR Therapeutics AG (CRSP) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $5.09B, listed on NASDAQ, employing roughly 393 people, carrying a beta of 1.74 to the broader market. CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Led by Samarth Kulkarni, public since 2016-10-19.
Short interest is the total number of shares currently sold short and not yet covered, reported bi-monthly by FINRA. Days to cover (short interest divided by average daily volume) indicates how long it would take short sellers to close positions, with higher values signaling greater squeeze potential.
- Settlement Date
- 2026-04-30
- Short Interest
- 22.5M
- Previous Short Interest
- 22.8M
- Change
- -1.18%
- Days to Cover
- 11.91
- Avg Daily Volume
- 1.9M
- Avg Days to Cover (24 reports)
- 10.38
Showing 24 bi-monthly FINRA short interest reports for CRISPR Therapeutics AG.
Learn how short interest is reported and how to read the data →
Frequently asked CRSP short interest questions
- What is the current CRSP short interest?
- As of the Apr 30, 2026 settlement, CRISPR Therapeutics AG (CRSP) short interest is 22.5M shares, a -1.18% change from the prior period. FINRA publishes short interest twice monthly on the 15th and last business day of each month under Rule 4560.
- What is the CRSP days-to-cover ratio?
- Days-to-cover is 11.91, calculated as short interest divided by average daily volume. It estimates how many trading days closing all short positions would consume given typical liquidity. Values above 5 days are commonly cited as elevated; values above 10 days are squeeze-relevant.
- How does CRSP short interest affect options pricing?
- High short interest changes options pricing through three mechanics: borrow-rebate effects (synthetic long stock trades below frictionless put-call parity by approximately the borrow rebate when shares are hard-to-borrow), gamma-squeeze setup risk (if dealers are short gamma against retail call buying, dealer hedge flow can amplify upward moves), and elevated event-vol pricing on names with squeeze potential. See the canonical short-interest documentation for the full mechanism.